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Abstract
Background: There is a marked variation in clinical phenotypes that have been associated with
mutations in FKRP, ranging from severe congenital muscular dystrophies to limb-girdle muscular
dystrophy type 2I (LGMD2I).
Methods: We screened the FKRP gene in two cohorts totaling 87 patients with the LGMD
phenotype.
Results:  The c.826C>A, p.L276I mutation was present in six patients and a compound
heterozygote mutation in a seventh patient. Six patients had a mild LGMD2I phenotype, which
resembles that of Becker muscular dystrophy. The other patient had onset before the age of 3
years, and thus may follow a more severe course.
Conclusion: These findings suggest that LGMD2I may be common in certain North American
populations. This diagnosis should be considered early in the evaluation of LGMD.
Background
Fukutin-related protein (FKRP) is encoded by the gene
FKRP and participates in the glycosylation of α-dystrogly-
can in the muscle fiber[1]. There is evidence to suggest
that the protein localizes to both the Golgi apparatus[1]
and the endoplasmic reticulum[2], with some debate over
the possibility that mislocalization of FKRP plays a role in
the pathogenesis of disease [3-5]. Mutations in FKRP can
cause a range of phenotypes, including MDC1C (a severe
congenital muscular dystrophy) [6], Walker-Warburg syn-
drome[7], muscle-eye-brain disease[7], a severe form of
limb-girdle muscular dystrophy type 2I (LGMD2I), and a
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mild form of LMGD2I[8]. One particular mutation,
c.826C>A, p.L276I, is by far the most common mutation
causing LGMD2I, present either in homozygote form or as
part of a compound heterozygote genotype [8-12]. Since
the original descriptions of these associations, it has
become evident that LGMD2I is one of the more common
LGMDs in the United Kingdom [13], Denmark[10], and
Brazil[12]. A recent series also suggests the same for the
United States[14]. We have similarly found that LGMD2I
may be one of the more common LGMDs in two North
American cohorts.
Methods
In the first cohort, 63 patients were ascertained either pro-
spectively at the Children's Hospital Boston Neuromuscu-
lar Program or by referral from other neurologists in
North America for the possible diagnosis of LGMD. Clin-
ical data collected included age of onset, pattern of muscle
involvement, family history, creatine kinase (CK) level in
serum, and cardiac involvement. All subjects had progres-
sive muscle weakness and myopathic findings on muscle
biopsy. We enrolled patients without a known molecular
etiology into the first cohort under an institutionally
approved protocol. Informed consent was obtained from
all patients in this cohort. In the second cohort, one of the
authors (AAA) screened 24 patients from his clinic with
the clinical diagnosis of LGMD for mutations in FKRP and
other genes known to cause LGMD, using clinically avail-
able genetic testing for mutations in CAPN3, DYSF, and
CAV3. Facioscapulohumeral muscular dystrophy and
Duchenne/Becker muscular dystrophies were excluded by
genetic testing. Dysferlinopathies were also excluded in
the second cohort by Western blot. In both cohorts,
patients thought to have Duchenne or Becker muscular
dystrophy without known mutations were included.
Many of the enrolled patients had muscle biopsies per-
formed at other centers, and thus the immunohistochem-
istry stains obtained vary from patient to patient. The
methods described below apply to the first cohort.
For exon 4 amplification, the primers used were agctgct-
ggacttgaccttc (forward) and tccaagtagatgcccaggtc (reverse).
The Fast Start Taq DNA Polymerase Kit (Roche Diagnos-
tics, Pleasanton, CA) was used to set up the PCR reactions,
which were run at 95°C for 4 minutes, followed by 35
cycles of 95°C for 30 seconds, 60°C for 30 seconds, and
72°C for 2 minutes, followed by 72°C for 7 minutes.
For the exon 4 sequencing reaction, the primers used were
ccgagtttgtggccctagta (forward) and ccagccttctctcatgctct
(reverse). The sequences were visualized on the 3730
DNA Analyzer (Applied Biosystems, Foster City, CA) and
interpreted using the Sequencher 4.6 software program
(Gene Codes Corporation, Ann Arbor, MI). Positive
results were confirmed on separate aliquots of DNA that
were processed and analyzed in a CLIA-approved DNA
diagnostic facility.
Fifty-six of the patients in cohort 1 were also screened for
mutations in CAV3  using direct sequencing methods
(primers kindly contributed by RR Bennett).
Results
Among the 63 LGMD patients in the first cohort, 40 were
male and 23 female. The age of onset ranged widely from
birth to 70 years. The ethnic backgrounds included 38
Caucasians, 7 Hispanic-Americans, 5 African-Americans,
4 Asian-Americans, and 9 unknown. Four patients in the
first cohort, all from the United States, were diagnosed
with LGMD2I based on mutations in FKRP. Among the 24
LGMD patients in the second cohort, 3 were diagnosed
with LGMD2I, 8 with Becker muscular dystrophy, 2 with
LGMD2A, 5 with dysferlinopathy (3 with LGMD2B, 2
with Miyoshi myopathy), 1 with FSHD (facial sparing),
and 5 are undiagnosed to date.
Demographic and clinical information on the seven
patients diagnosed with LGMD2I are listed in Table 1.
Patient 1 had onset of symptoms as a toddler, while the
others developed symptoms later in childhood or in early
adulthood. Age of onset was defined as the age when
patients recalled first having motor difficulties, not the age
of presentation. None had significant motor delays. Each
patient was sporadic, consistent with a recessive pattern of
inheritance. The pattern of weakness was predominantly
proximal, with the lower extremities more severely
affected than the upper extremities. Facial strength was
generally preserved, while mild scapular winging was
present in some patients. Evidence of mild cardiac or res-
piratory dysfunction was present in some patients. All of
the patients were ambulatory at the last known follow-up.
Muscle biopsy was performed in patients 1 through 6.
Histochemical stains demonstrated variation in fiber size,
degenerating and regenerating fibers, increased endomy-
sial or perimysial connective tissue, and fiber splitting.
Immunohistochemical findings are listed in Table 1.
The first six patients described in Table 1 have
homozygous c.826C>A, p.L276I mutations in FKRP. The
seventh patient is a compound heterozygote, with a 169
base pair deletion in one allele and a c.328C>T, p.R110W
mutation in the other allele. The entire coding region of
FKRP was screened in the remaining 59 patients from the
first cohort who did not have the common mutation. No
other mutations were identified. No mutations in CAV3
were identified in either cohort.
Discussion
It is becoming increasingly clear that LGMD2I, caused by
mutations in FKRP, is one of the more common LGMDs,B
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Table 1: Clinical features of patients with FKRP mutations
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7
Gender Male Male Female Male Female Female Male
Ethnicity - Causasian Caucasian Caucasian Caucasian Caucasian Asian
Onset 34 months 1st grade 18–19 years Childhood 23 years Childhood 25 years
Chief complaint Difficulty rising Difficulty running Exertional myalgias Difficulty running Difficulty with stairs Difficulty running Difficulty with stairs
Calf pseudohypertrophy Present - None Present None Present Medial calf atrophy
Heel cords Contracted - Normal Unknown Contracted Normal -
Facial strength Normal Mild weakness Normal Normal Normal Normal Normal
Scapular winging - - - - Subtle Subtle Subtle
Proximal upper extremity strength - 4+ 4- 5 4- 4 4+
Distal upper extremity strength - 5 5 5 4+ to 5 4+ 5
Proximal lower extremity strength Weak 2+ to 3+ 3- to 4- 2 to 3 2 3- to 3 3- to 4-
Distal lower extremity strength - 5 5 5 4 4 5- to 5
Reflexes 2+ Trace 2+ 1+ to 2+ 1+ to 2+ 2+ 2+
FVC (% predicted) - - - - 2.72L (83%) 2.87L (75%) 3.03L (56%)
Echocardiogram (ejection fraction) Normal - Normal (55%) Angiogram normal Normal (>55%) ~45% (>55%)
Creatine kinase (U/L) 5,438 5,000+ 1,945 3–4 times normal 1,136 5,031 6,560 to 10,642
Dystrophin duplication/deletion None - None None - - -
Age at biopsy 3 1/2 years 17 years 30 years 51 years 27 years 25 years -
Muscle sampled Left quadriceps Left biceps Deltoid Left quadriceps Biceps Deltoid -
Dystrophin staining Normal Normal Normal Normal Normal Normal -
Merosin staining Normal - - - - Decreased -
Sarcoglycans (α,β,γ,δ) Normal Normal Normal - Normal Normal -
β-dystroglycan Normal - Normal - Normal Normal -
Spectrin - Normal Normal - Normal Normal -
FKRP mutation c.826C>A, p.L276I 
(homozygous)
c.826C>A, p.L276I 
(homozygous)
c.826C>A, p.L276I 
(homozygous)
c.826C>A, p.L276I 
(homozygous)
c.826C>A, p.L276I 
(homozygous)
c.826C>A, p.L276I 
(homozygous)
del 1006–1174 (169 
basepair frameshift, 
heterozygous), 
c.328C>T, p.R110W 
(heterozygous)
-, not done or not assessed; FVC, forced vital capacity; extremity strength graded on Medical Research Council (MRC) scaleBMC Musculoskeletal Disorders 2007, 8:115 http://www.biomedcentral.com/1471-2474/8/115
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possibly rivaling LGMD2A (calpainopathy) in preva-
lence[10]. In particular, the homozygous c.826C>A,
p.L276I mutation is the most common FKRP mutation in
several series of Caucasian populations [8-10,12-15].
There is only one study to date that suggests otherwise,
listing compound heterozygotes involving the c.826C>A
mutation as being most abundant[11]. The homozygous
form of the common mutation causes the milder pheno-
type of LGMD2I with onset in childhood or early adult-
hood and a slow progression. Ambulation appears to be
preserved until at least middle age, suggesting that some
affected individuals may not seek medical attention and
may not be diagnosed due to the mild nature of their
symptoms. The more severe phenotypes (severe LGMD2I,
MDC1C, Walker-Warburg syndrome, and muscle-eye-
brain disease) are generally caused by other mutations.
There have been recent reports of patients with LGMD2I
having previously been diagnosed incorrectly with a dys-
trophinopathy, thus it is important to confirm a molecu-
lar diagnosis for any of the muscular dystrophies[9].
A clinical comparison of the patients in our series to those
in others is best made by focusing on the patients who
have the common homozygous c.826C>A mutation[8-
10,12,13]. The clinical courses of these patients to date
correlate well across the series, especially with regard to
the preservation of ambulation in most individuals into
middle adulthood. The age of onset in several of our
patients is at the earlier end of the range observed previ-
ously. In our series, cardiac and pulmonary complications
are present in a minority of patients, consistent with
another series[15]. However, some of our subjects have
not yet been screened for these conditions, and other
series suggest a high prevalence of both complica-
tions[16,17].
Conclusion
LGMD2I may be one of the more common forms of
LGMD in some North American populations. The most
common mutation generally cause a mild phenotype, but
these patients have clearly elevated creatine kinase levels,
making it easy to screen for this disorder in patients with
mild gait difficulties. As further cohorts of LGMD patients
are analyzed, the incidence of each subtype will become
more clearly defined.
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